The Integrated Molecular Profiling of Multiple Myeloma and Related Plasma Cell Dyscrasias using Blood and Bone Marrow Samples (IMMAGINE)
Aim/goals:
Comparison of molecular profiling data from bone marrow (BM)-derived tumour samples to blood plasma-derived cfDNA, and to correlate BM and blood molecular profiles with clinical outcome data
To explore whether genomic and transcriptomic profiles from WGTS improve current risk-stratification methods that are derived from cytogenic-based methods (e.g. chromothripsis, mutation burden, previously described expression signatures)
To explore whether profiles obtained from tumour WGS at baseline can inform ctDNA detection from plasma WGS profiling during periods of disease remission to improve minimal residual disease monitoring
Summary:
The Integrated Molecular Profiling of Multiple Myeloma and Related Plasma Cell Dyscrasias using Blood and Bone Marrow Samples (IMMAGINE) study seeks to improve our understanding of the biological underpinnings of myeloma at all stages by applying advanced molecular platforms including next generation sequencing to tumor and blood samples collected from patients with MM.
